In this podcast, Jennifer Curtis and David Jackson share valuable insights on global commercial excellence. They highlight strategies to optimize product launches and maximize revenue potential, based on recent research conducted by ZS on the top 25 pharma companies.

Jennifer Curtis, Pranav Srivastava and Surbhi Puri discuss customer experience in cell and gene therapy (CGT), drawing on recent ZS patient experience study outcomes.

Innovation is far more diffuse today, reflecting the increasingly fragmented nature of the pharma industry. On top of that, late-stage deals significantly underperform compared to early-stage strategy. So pharma may be in line for a shift in strategy. This edition of the “Inside Global Pharma” podcast features a discussion on an innovation constellation model, a focused and intentional strategy that emphasizes early-stage activity to drive long-term success. 

On this episode of Inside Global Pharma, Jennifer Curtis and Maria Whitman discuss trends in global launches—from the drivers of commercial success to how companies can best map realistic opportunities for their pipeline assets. Listen to hear their predictions for what the future looks like including opportunities, challenges and priority areas to invest for success.

Highlights from the episode: 

•         Today, 40% of launches fail to meet expectations due to smaller and fragmented opportunities, increasing complexity of customer groups and global pharma’s more compressed resources 

•         Economic pressures and pipeline evolution from blockbusters to more targeted therapies necessitate a shift from traditional “command and control” to “needs-driven” launch models 

•         No-regret moves for pharma include making strategic decisions that balance short versus long-term capability development, focusing on customer needs, building digital capabilities and embracing more agile launch models

In this edition of the IGP podcast, Jennifer Curtis connects with Josh Hattem to discuss trends in oncology portfolio strategy, building on a previous IGP episode, “The value of focus.”

Highlights from the episode include:

·       The oncology therapy area’s future is not as certain as it was in the past; blockbuster launches sold 47% higher on average in 2012-2016 compared to 2017-2021 

·       A range of factors contributed to this drop, including intense competition, smaller, more fragmented opportunities and the entrance of emerging pharma players into the space

·       The latest ZS research suggests intentional use of the customer lens early in portfolio strategy development could help companies “win” in oncology by enhancing “share of mind”.

Listen to the podcast.

Jennifer Curtis connects with Ben Hohn to discuss trends in first launch and partnering, focusing on emerging pharma and changes in strategic decision-making.

Highlights from the episode include:

·         Emerging pharma is driving industry innovation and a substantial share of total pharma pipeline

·         Although Europe is typically considered a more challenging market, emerging pharma companies have seen success both in solo and partnered commercialization efforts

·         This is partly due to ecosystem shifts, for example reduced reliance on acquisition by larger firms at the asset development stage, as well as an increased focus on specialist and orphan assets

In this edition, Jennifer Curtis connected with Hensley Evans and Tina Shepley to discuss the need for more market-shaping activities geared towards patients to ensure a successful product launch. 

Highlights from the episode include: 

·       Activities that traditionally focus on HCPs and how patient-targeted campaigns are often “tick-the-box” exercises 

·       Pharma’s need to invest early and strategically to understand the patient experience and define engagement objectives

·       Advice for manufacturers to go beyond the brand needs and understand patient needs in individual launch markets

Jennifer Curtis and Jeffrey Moore discuss recent ZS insights and trends in #customerengagement.

The road to commercializing cell and gene therapies has been long, with many highs and lows along the way. However, the last few years have seen strong market growth and a very crowded pipeline. In this episode, ZS’s Jennifer Curtis and Sankalp Sethi discuss ongoing challenges and what it will take to successfully launch and commercialize these cutting-edge therapies in the U.S. and abroad.